{"id":"ppv23-alone","safety":{"commonSideEffects":[{"rate":"20–50","effect":"Injection site erythema, induration, or pain"},{"rate":"5–15","effect":"Fever"},{"rate":"5–10","effect":"Myalgia or arthralgia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL310671","moleculeType":"Small molecule","molecularWeight":"183.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPV23 (Pneumovax 23) contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated to a carrier protein or presented as a polysaccharide mixture. Upon vaccination, these antigens trigger B-cell and T-cell responses, generating opsonizing antibodies that enhance phagocytosis and complement-mediated killing of pneumococcal bacteria, thereby providing protection against invasive pneumococcal disease and pneumonia caused by these serotypes.","oneSentence":"PPV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:00.925Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children ≥2 years"},{"name":"Prevention of pneumococcal pneumonia in high-risk populations (elderly, immunocompromised, chronic disease)"}]},"trialDetails":[{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT02637583","phase":"PHASE4","title":"Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2017-10-18","conditions":"Pneumococcal Infections","enrollment":123},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404},{"nctId":"NCT03802994","phase":"EARLY_PHASE1","title":"Pneumococcal Conjugate Vaccine in Aging Renal Transplant","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2018-11-01","conditions":"Renal Transplantation, Aging","enrollment":57},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT03039491","phase":"EARLY_PHASE1","title":"Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2015-09-01","conditions":"HIV Lipodystrophy, Aging","enrollment":160},{"nctId":"NCT02357823","phase":"","title":"Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults","status":"WITHDRAWN","sponsor":"University of Siena","startDate":"2015-01","conditions":"HIV, Pneumococcal Infections","enrollment":""},{"nctId":"NCT02285036","phase":"PHASE3","title":"Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2012-09","conditions":"Pneumococcal Infectious Diseases","enrollment":1660},{"nctId":"NCT02225327","phase":"PHASE4","title":"MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2013-10","conditions":"Influenza, Human, Pneumococcal Infections","enrollment":224}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":33,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"PPV23 alone","genericName":"PPV23 alone","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"PPV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia) in adults and children ≥2 years, Prevention of pneumococcal pneumonia in high-risk populations (elderly, immunocompromised, chronic disease).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}